Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on developing and commercializing hospital specialty products. The Company's development is focused on products that treat gastrointestinal infections and related diseases. Its two products OPT-822/821 and CEM-101 (OP-1068) are in clinical development. Optimer's products include Fidaxomicin and Solithromycin under anti-infectives, and OPT-822/821 under other therapeutic areas. In January 2011, its majority owned subsidiary, Optimer Biotechnology, Inc. (OBI) conducted a Phase 2/3 clinical, trial to evaluate OPT-822/821for the treatment of metastatic breast cancer. On May 27, 2011, the United States Food and Drug Administration (FDA) approved DIFICID(fidaxomicin) tablets, its antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). In October 2013, Cubist Pharmaceuticals, Inc announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
SymbolNASDAQ:OPTR
CUSIP68401H10
Phone+1-201-3338819
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
Optimer Pharmaceuticals (NASDAQ:OPTR) Frequently Asked Questions
What is Optimer Pharmaceuticals' stock symbol?
Optimer Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPTR."
Has Optimer Pharmaceuticals been receiving favorable news coverage?
News stories about OPTR stock have trended positive recently, Accern reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Optimer Pharmaceuticals earned a media and rumor sentiment score of 0.28 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 46.70 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for Optimer Pharmaceuticals.
How do I buy shares of Optimer Pharmaceuticals?
Shares of OPTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Optimer Pharmaceuticals?
Optimer Pharmaceuticals' mailing address is 101 Hudson St Ste 3501, JERSEY CITY, NJ 07302-3915, United States. The biopharmaceutical company can be reached via phone at +1-201-3338819.
MarketBeat Community Rating for Optimer Pharmaceuticals (NASDAQ OPTR)
MarketBeat's community ratings are surveys of what our community members think about Optimer Pharmaceuticals and other stocks. Vote "Outperform" if you believe OPTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
